Summary The short arm of the chromosome 11, known to harbour a number of putative and established tumour-suppressor genes, is frequently hypermethylated in various human neoplasms. We subjected the promoter regions of two genes residing at lip, namely the tumour-suppressor gene WT1 (Wilms' tumour gene) (11p13) and the calcitonin gene (11p15.5), to methylation analysis in human sporadic colorectal cancer using genomic sequencing. Both genes showed significant hypermethylation of CpG sites within their promoter regions in adenomas and carcinomas compared with normal colonic mucosa. Although the WT1 promoter region was significantly hypermethylated, two CpG sites located in Spl motifs were unmethylated in the majority of cases (68-74% of carcinomas). The expression of WT1 gene, as revealed by in situ hybridization, showed no differences between normal colonic mucosa and malignant carcinoma. Together with earlier observations, our present results support the view that the short arm of human chromosome 11 is subjected to widespread regional hypermethylation in various human malignancies.
For many years, changes in DNA methylation have been related to cancer progression, yet the significance of these epigenetic alterations to malignant transformation and progression has remained unknown. During the past few years, the technical development of methylation analysis of genomic DNA has made it possible to study the methylation status of individual CpG sites with the aid of genomic sequencing.
Hypermethylation of the regulatory sequences of genes usually correlates with total silencing of the gene or its reduced expression (Jones, 1996) . Moreover, the methylation of the fifth carbon of cytosine increases the risk of spontaneous deamination of cytosine to uracil, resulting in C to T transitions (Laird and Jaenisch, 1994) , as the mutation rate of 5-methylcytosine is 10-to 40-fold higher than that of unmethylated cytosine. Therefore, the 5-methylcytosine can be considered as an endogenous mutagen (Laird and Jaenisch, 1994; Tornaletti and Pfeifer, 1995) .
Hypermethylation-based inactivation of tumour-suppressor genes may be one of the mechanisms leading to malignant transformation. As hypermethylated genes can potentially be reactivated by inhibition of DNA methylation (Jones, 1996) , this may offer a novel approach to cancer chemotherapy. Thus, the possibility to demethylate tumour-suppressor genes and restore their expression can be used as a means for therapeutic intervention in cancer. In fact, inhibition of DNA methyltransferase by antisense expression construct directed to the methyltransferase mRNA has indicated that alteration in DNA methylation pattern can be sufficient to reverse cell transformation (MacLeod and Szyf, 1995) . In Received 30 September 1996 Revised 9 April 1997 Accepted 15April 1997 Correspondence to: MO Hiltunen addition to hypermethylation of tumour-suppressor genes, hypomethylation of oncogenes is also apparently involved in malignant transformation and tumour progression. Thus, the assessment of DNA methylation status of tumour-suppressor genes and oncogenes would reveal potential targets for the therapy based on the modification of DNA methylation.
In colorectal carcinogenesis, genomic hypomethylation (Goelz et al, 1985; Feinberg et al, 1988 ) is an early epigenetic event occurring in association with genetic changes, such as mutations in the APC (adenomatous polyposis coli), DCC (deleted in colon cancer) and p53 genes (Hamilton, 1992) . The mutations of the APC gene have been shown to be causally related to familial adenomatous polyposis (FAP) (Cunningham and Dunlop, 1994) . FAP patients form multiple adenomatous polyps in early adulthood throughout the colon and rectum and have a high risk of developing colon cancer. In addition to common genetic alterations in colorectal cancer, c-myc oncogene hypomethylation has been shown to occur in one-half of adenomas and two-thirds of adenocarcinomas (Sharrard et al, 1992) . While overall genomic hypomethylation is associated with colorectal cancer (Goelz et al, 1985; Feinberg et al, 1988) , some individual genes, such as the oestrogen receptor gene (Issa et al, 1994) and the APC gene (Hiltunen et al, i997) , appear to be hypermethylated.
The short arm of human chromosome 11 harbours a number of putative or established tumour-suppressor genes (Ichikawa et al, 1992; Lichy et al, 1992; Loh et al, 1992; Strohmeyer, 1993) . Interestingly, I lp has been shown to be hypermethylated in various human neoplasms (Bustros et al, 1988) . The WTI gene (lIpl3) is a tumour-suppressor gene that is expressed in a tissuerestricted manner (Fraizer et al, 1994) . The WT1 gene encodes a transcription factor containing four zinc fingers at the carboxy terminus with a proline-rich amino terminus and belongs to the early growth response (EGR) family (Rauscher et al, 1990 
In situ hybridization
Tissue samples were cut into 1 0-,um sections with a cryostat (Leica CM3000, Germany) at -20°C, collected onto precleaned slides (Menzel-Glaser, Germany) and processed for in situ hybridization using the method as described in Schalling et al (1988) . The oligonucleotide probe (5'-CGGAGCCCA'TT'GCTGAGGCTCA-GACCCGGACGCCCCGCGGCTCCTCCGGCCCTGG-3') used was 3' end labelled using terminal deoxynucleotidyltransferase (New England Nuclear, Boston, MA, USA) and 35S-labelled deoxyadenosine triphosphate (New England Nuclear). After hybridization, the sections were either exposed to Kodak XAR-5 film for 13 days or coated with Kodak NTB2 emulsion and exposed for 18 days. Hybridization experiments, with non-specific probe as well as hybridization in the presence of a 200-fold excess of unlabelled WTI probe, were used to confirm the specificity of the hybridization.
DNA extraction and bisulphite modification
Tissue samples (50-200 mg) from normal-appearing colonic tissue were homogenized in 1 ml of 1 x PBS (phosphate-buffered saline) and centrifuged for 5 min at 1000 g; the supematant fraction was discarded and the pellet was homogenized in 500 jl of x PBS. The homogenate was suspended in 5 ml of digestion buffer (10 mm Tris, 1 mM EDTA, 0.3 M sodium acetate, 1% sodium dodecyl sulphate, pH 8.0), and 50 jl of proteinase K (Boehringer Mannheim, Germany) solution (20 mg ml-') was added to each sample. Selected parts (cut in 5-gm sections) from adenomas and adenocarcinomas were directly added to the digestion buffer. The samples were incubated at +37°C for 12-18 h with slow continuous shaking. Then RNAase A (Sigma, St Louis, MO, USA) treatment was carried out by adding 50 jil of RNAase A solution (10 mg ml-') to each sample followed by incubation at +37°C for 30 min. The samples were extracted twice with 5 ml of phenol and once with 5 ml of chloroform-isoamylalcohol (24:1) mixture. DNA was precipitated with ethanol in the presence of 3 M sodium acetate. DNA was dissolved in Tris-EDTA buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).
The DNA concentration was measured by Lambda Bio spectrometer (Perkin Elmer, Germany) and 10 jig of DNA was used for bisulphite modifications, which were carried out according to our modified method (Myoihanen et al, 1994) .
Amplification of the WT1 gene promoter region Polymerase chain reaction (PCR) products were obtained by carrying out two PCR reactions for each sample. In order to amplify the WTI gene promoter region (Hofmann et al, 1993) , primers were selected to cover the region of 514 bp, from -509 to +5 with respect to transcription initiation site (GenBank accession number X74840). For the amplification, 100 ng of recently modified DNA was used in a 50-jl PCR mixture containing: 20 pmol of the upper primer (5'-GATAGTTTTA-GAAGTAAGAGTTAGATTTAAG-3'), 20 pmol of the lower primer (5'-CCTAACTACCCTCAACTTCCC-3'), 1.0 mM magnesium chloride, 0.2 mm dNTPs and 1 x buffer. The conditions for the first PCR cycle were +96°C for 4 min for denaturation and British Journal of Cancer (1997) 76(9) The amplification was carried out according to our recently developed method (Hakkarainen et al, 1996) . In brief, primers for first PCR were selected to cover a 517-nucleotide region (GenBank accession number X15943). The reaction mixture for PCR contained 20 pmol of the upper primer (5'-TATIlTGGTAGGGTTTGGATrAGA-3'), 20 pmol of the lower primer (5'-CCAAAA-TCTCG/AAAACTCACCTAAC-3'), 1. 
Sequencing reactions
The sequencing reactions for the products of the second PCR were carried out using the AutoRead kit (Pharmacia, Sweden) with fluorescently labelled primers. Reaction products were analysed on the ALF (Pharmacia) DNA sequencer using the AM V3.02 program. The methylation status of the final sequence was evaluated by grading the CpG methylation into five categories: 100%, 75%, 50%, 25% and 0%, as described in Myohanen et al (1994) .
Statistical analyses
The two-tailed Student's t-test was used to evaluate the statistical significances.
RESULTS
Methylation of the WT1 promoter region in normal colonic mucosa, premalignant adenoma and colorectal carcinoma Genomic sequencing was used to analyse the methylation of the WTI tumour-suppressor gene promoter region. The method consists of DNA modification with the aid of bisulphite, PCR amplification of the selected region from modified DNA and direct sequencing of the PCR product. The amplified region of the WTI gene promoter contains, altogether, 28 CpG dinucleotides, for which the methylation status of the first 24 CpG sites was determined (Figure 1 ). The amplified region also contains two SpI motifs 5'-CCCGCCC-3' (Fraizer et al, 1994) , including CpG sites 3 and 16. In the normal colonic tissue (n = 14), the WTI gene promoter was completely unmethylated, whereas the base-specific analysis of methylated cytosines revealed significant hypermethylation in premalignant adenomas (n = 8) and, to a slightly lesser extent, in carcinomas (n = 19), as shown in Figure 2 . As shown in Figure 3A , the CpG site 3 within the first Spl motif was unmethylated in 74% (14 out of 19) of cancers and the CpG site 16 within the second Spl motif was unmethylated in 68% (13 out of 19) of cancers. The observation was similar in adenomas in which the first Spl motif was unmethylated in 50% of cases and the second Spl motif was unmethylated in 63% of cases. In normal colonic tissue, all samples examined showed completely unmethylated Spl motifs.
Methylation of the calcitonin gene promoter in normal colonic mucosa, adenoma and colorectal carcinoma
We used the same methodology to study the methylation status of the calcitonin gene promoter in colorectal cancer. For genomic sequencing, we used a 490-nucleotide fragment (covering the nucleotides -379 to +110 with respect to transcription start site) amplified after bisulphite modification. This fragment contained 26 CpG dinucleotides, of which the methylation status for the first 25 CpG sites was determined. As shown in Figure 2 , the calcitonin gene promoter was significantly more methylated in adenomas (n = 8) and carcinomas (n = 419) than in normal colonic mucosa (n = 14). The amplified calcitonin gene promoter region also contains two putative Sp 1 motifs (Figures 1 and 3 ), but there were no significant differences in methylation status between CpG sites located to Spl motifs and other CpG dinucleotides, as seen in the WTI promoter region. In Figure 5 , raw sequence data illustrate the primary outcome of modified and PCR amplified DNA.
Expression and localization of the WT1 mRNA in normal colonic mucosa and colorectal carcinoma Because of the heterogeneous cell population in colonic tissue, the in situ hybridization method was selected to analyse localization and intensity of WTJ mRNA expression in normal colonic tissue and in carcinomas. The WTI mRNA was expressed in epithelial cells of normal colonic mucosa as shown in Figure 4A and D.
As also shown in Figure 4E , a quantitatively similar expression pattern was seen in tumour samples, in spite of the fact that the promoter region of the WTI gene was on average 70% methylated in comparison with the totally unmethylated control samples.
DISCUSSION
Two types of DNA methylation changes appear to be connected, at least potentially, with the progression of malignant tumours: hypomethylation-induced activation of oncogenes and hypermethylation-based silencing of tumour-suppressor genes (Laird and Jaenisch, 1994 (Jones, 1996) , some recent reports suggest that a modification of gene methylation can be used as a therapeutic approach. In fact, DNA that resulted in limited genomic hypomethylation that was associated with a reversal of malignant transformation (MacLeod and Szyf, 1995) .
The molecular carcinogenesis of human colorectal cancer is relatively well known. It involves distinctly ordered alterations in common oncogenes and tumour-suppressor genes (Hamilton, 1992) . Genomic hypomethylation is a special feature of colorectal cancer occurring at an early stage of the disease (Goelz et al, 1985; Feinberg et al, 1988) , although regional hypermethylation (Issa et al, 1994; Hiltunen et al, 1997) and increased activity of DNA methyltransferase (Issa et al, 1993) have also been reported with progression of the tumour.
We recently developed a method making it possible to elucidate base-specific methylation status of any known sequence of interest (Myohanen et al, 1994) . By using this method, we showed that the calcitonin gene was distinctly hypermethylated in breast cancer (Hakkarainen et al, 1996) . Here, we show that the promoter of the calcitonin gene is likewise hypermethylated in colorectal cancer. The calcitonin gene hypermethylation in premalignant colonic adenomas and in carcinomas has already been reported using restriction endonucleases (Silverman et al, 1989) . We also subjected the promoter region of the WTI tumoursuppressor gene, another gene residing at the short arm of chromosome 11, to genomic sequencing and found that it was significantly more methylated in colorectal cancer than in normal mucosa. However, this methylation of the WTI gene apparently did not affect its expression as revealed by in situ hybridization experiments. WTI gene expression was limited to the epithelial cells of both the normal mucosa and the tumours. The observation that 70-80% methylation of the CpG sites of the promoter region of the WTI gene did not appear to have as effect on its expression (Figure 4 ) suggests that this gene is mainly regulated by factors other than DNA methylation. The facts that the CpG sites within Spl motifs were significantly less methylated than other CpG dinucleotides ( Figure 3 ) and that the mRNA expression was not altered may indicate an involvement of Spl-based regulation. If WTI expression is required in the cell, the important sites for transcription will be protected from DNA methylation to allow constitutive expression of the gene. This might also be the case, at least for some of the reported gene hypermethylations, in cancers. Thus, it is important to study the corresponding mRNA expression with gene methylation, and each gene should be considered individually. Although the expression of the WTI gene appears to be tightly regulated throughout development, its promoter readily functions in all cell lines tested. The gene seems to contain a transcriptional silencer element in the third intron (Hewitt et al, 1995) . In addition to this silencer, the WTI gene has been reported to possess a functional antisense promoter located in the first intron that negatively regulates gene expression (Malik et al, 1995) .
Our results show constitutive epithelial cell-localized expression of the WT] tumour suppressor gene in the progression of colorectal cancer and, in addition, genomic sequencing results support the notion that the short arm of human chromosome 11 is subjected to widespread regional hypermethylation in human colorectal cancer.
